
Contrave: An Upcoming Diet Drug
Contrave, otherwise known as NB32, is finally getting the opportunity to help individuals lose weight in the United States. The diet drug was rejected by the U.S. Food and Drug Administration (FDA) when it was first introduced in 2011 due to lack of solid data about heart risk. However, it is getting a second chance, as it successfully went through a preliminary stage in June 2014, and is expected to gain final approval in September 2014.